Premium
Nicotinic acid/laropiprant: a new lipid‐modifying therapy
Author(s) -
Chaplin Steve,
Evans Marc
Publication year - 2009
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.556
Subject(s) - medicine , nicotinic agonist , pharmacology , receptor
Tredaptive is a combination of nicotinic acid and laropiprant for the treatment of dyslipidaemia and primary hypercholesterolaemia. In our New products review, Steve Chaplin discusses the clinical data relating to its efficacy and side‐effects, and Dr Marc Evans describes its place in therapy. Copyright © 2009 Wiley Interface Ltd